Skip to main content
. Author manuscript; available in PMC: 2021 Jun 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):272–279. doi: 10.1097/QAI.0000000000002461

Table 1.

Regional and state-by-state prevalence of methamphetamine use between baseline and 12 month follow up, Together 5,000 cohort study, n = 4786, 2017 – 2019

Total participants
n = 4786, 100%
Abstinent: No use at BL or 12M
n = 4127, 86.2%
Baseline only: BL use only, no use between BL and 12M
n = 143, 3.0%
Incident use: Indicated use between BL and 12M
n = 94, 2.0%
Persistent use: Baseline and 12M use
n = 422, 8.8%
Frequency (%) Freq uency (%) Frequency (%) Frequency (%) Frequency (%)
Northeast 738 (15.4) 660 (89.4) 24 (3.3) 14 (19) 40 (5.4)
 Connecticut 28 (0.6) 24 (85.7) 2 (7.1) 0 (0.0) 2 (7.1)
 Maine 5 (0.1) 5 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Massachusetts 79 (1.7) 69 (87.3) 6 (7.6) 2 (2.5) 2 (2.5)
 New Hampshire 9 (0.2) 7 (77.8) 0 (0.0) 1 (11.1) 1 (11.1)
 New Jersey 72 (1.5) 64 (88.9) 1 (1.4) 2 (2.8) 5 (6.9)
 New York 394 (8.2) 359 (91.1) 11 (2.8) 7 (1.8) 17 (4.3)
 Pennsylvania 131 (2.7) 113 (86.3) 3 (2.3) 2 (1.5) 13 (9.9)
 Rhode Island 18 (0.4) 17 (94.4) 1 (5.6) 0 (0.0) 0 (0.0)
 Vermont 2 (0.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Southeast 2214 (46.3) 1894 (85.5) 62 (2.8) 50 (2.3) 208 (9.4)
 Alabama 74 (1.5) 61 (82.4) 3 (4.1) 2 (2.7) 8 (10.8)
 Arkansas 20 (0.4) 17 (85.0) 1 (5.0) 0 (0.0) 2 (10.0)
 Delaware 5 (0.1) 5 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
 District of Columbia 37 (0.8) 32 (86.5) 0 (0.0) 0 (0.0) 5 (13.5)
 Florida 503 (10.5) 424 (84.3) 8 (1.6) 18 (3.6) 53 (10.5)
 Georgia 256 (5.4) 214 (83.6) 13 (5.1) 6 (2.3) 23 (9.0)
 Kentucky 42 (0.9) 37 (88.1) 0 (0.0) 0 (0.0) 5 (119)
 Louisiana 77 (1.6) 60 (77.9) 4 (5.2) 3 (3.9) 10 (13.0)
 Maryland 58 (1.2) 54 (93.1) 1 (1.7) 2 (3.5) 1 (1.7)
 Mississippi 28 (0.6) 23 (82.1) 1 (3.6) 1 (3.6) 3 (10.7)
 North Carolina 182 (3.8) 158 (86.8) 4 (2.2) 3 (1.7) 17 (9.3)
 Oklahoma 52 (1.1) 46 (88.5) 4 (7.7) 0 (0.0) 2 (3.9)
 South Carolina 59 (1.2) 56 (94.9) 0 (0.0) 0 (0.0) 3 (5.1)
 Tennessee 62 (1.3) 53 (85.5) 3 (4.8) 1 (1.6) 5 (8.1)
 Texas 647 (13.5) 554 (85.6) 19 (2.9) 12 (1.9) 62 (9.6)
 Virginia 92 (19) 83 (90.2) 1 (1.1) 2 (2.2) 6 (6.5)
 West Virginia 20 (0.4) 17 (85.0) 0 (0.0) 0 (0.0) 3 (15.0)
Midwest 729 (15.3) 650 (89.2) 15 (2.1) 15 (2.1) 49 (6.7)
 Illinois 185 (3.9) 173 (93.5) 3 (1.6) 3 (1.6) 6 (3.2)
 Indiana 76 (1.6) 60 (79.0) 3 (4.0) 4 (5.3) 9 (11.8)
 Iowa 29 (0.6) 26 (89.7) 1 (3.5) 2 (6.9) 0 (0.0)
 Kansas 29 (0.6) 26 (89.7) 1 (3.5) 1 (3.5) 1 (3.5)
 Michigan 67 (1.4) 62 (92.5) 1 (1.5) 2 (3.0) 2 (3.0)
 Minnesota 60 (1.3) 52 (86.7) 3 (5.0) 0 (0.0) 5 (8.3)
 Missouri 75 (1.6) 66 (88.0) 1 (1.3) 1 (1.3) 7 (9.3)
 Nebraska 18 (0.4) 16 (88.9) 0 (0.0) 0 (0.0) 2 (11.1)
 North Dakota 6 (0.1) 4 (66.7) 0 (0.0) 1 (16.7) 1 (16.7)
 Ohio 117 (2.4) 104 (88.9) 1 (0.9) 0 (0.0) 12 (10.3)
 South Dakota 6 (0.1) 5 (83.3) 0 (0.0) 0 (0.0) 1 (16.7)
 Wisconsin 61 (1.3) 56 (91.8) 1 (1.6) 1 (1.6) 3 (4.9)
West 1084 (22.7) 904 (83.4) 42 (3.9) 13 (1.2) 125 (11.5)
 Alaska 10 (0.2) 9 (90.0) 0 (0.0) 0 (0.0) 1 (10.0)
 Arizona 89 (19) 70 (78.7) 4 (4.5) 3 (3.4) 12 (13.5)
 California 550 (11.5) 450 (81.8) 23 (4.2) 6 (1.1) 71 (12.9)
 Colorado 99 (2.1) 85 (85.9) 5 (5.1) 1 (1.0) 8 (8.1)
 Hawaii 12 (0.3) 6 (50.0) 1 (8.3) 2 (16.7) 3 (25.0)
 Idaho 20 (0.4) 17 (85.0) 1 (5.0) 0 (0.0) 2 (10.0)
 Montana 14 (0.3) 11 (78.6) 0 (0.0) 0 (0.0) 3 (21.4)
 Nevada 52 (1.1) 41 (78.9) 4 (7.7) 1 (1.9) 6 (11.5)
 New Mexico 22 (0.5) 22 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Oregon 64 (1.3) 60 (93.8) 2 (3.1) 0 (0.0) 2 (3.1)
 Utah 48 (1.0) 35 (72.9) 2 (4.2) 0 (0.0) 11 (22.9)
 Washington 100 (2.1) 96 (96.0) 0 (0.0) 0 (0.0) 4 (4.0)
 Wyoming 4 (0.1) 2 (50.0) 0 (0.0) 0 (0.0) 2 (50.0)
Territories
 Puerto Rico 19 (0.4) 17 (89.5) 0 (0.0) 2 (10.5) 0 (0.0)
 APO or FPO or DPO 2 (0.0) 2 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)

BL: Baseline (reported at BL with a 3 month recall window), 12M: 12 months (reported at month 12 with a 12 month recall window)